Ontology highlight
ABSTRACT: Background
Trastuzumab deruxtecan (TDXd) is an antibody-drug conjugate that has demonstrated impressive activity in randomized controlled clinical trials in the context of patients with HER2-amplified and HER2-low metastatic breast cancer. We aimed to review the activity and adverse event profile of TDXd in heavily pretreated breast cancer patients in real practice.Methods
We describe a single-center retrospective case series of metastatic breast cancer patients who were treated with TDXd. The outcomes of interest were the overall response rate, overall survival, progression-free survival and grade 4-5 adverse events. Objective responses and PFS were assessed in accordance with RECIST 1.1 criteria.Results
We identified 38 patients treated with TDXd. Of these, 15 pat
SUBMITTER: Lazaratos AM
PROVIDER: S-EPMC11763754 | biostudies-literature | 2024 Dec
REPOSITORIES: biostudies-literature